Ertu Tablet 15 mg ( INVOKANA) is an oral medication for the treatment of type 2 diabetes (T2D). It belongs to a group of medications called sodium-glucose cotransporter-2 (SGLT2) inhibitors. SGLT2 inhibitors work by preventing the reabsorption of glucose from the kidneys, increasing the glucose excretion in the urine and reducing the levels of glucose in the blood.
Ertu Tablet 15 mg is used to treat adults with type 2 diabetes. It is used along with diet and exercise to lower blood sugar levels and improve glycemic control. It can also be used with other diabetes medications, such as metformin or pioglitazone.
Ertu Tablet 15 mg works by blocking the kidney's reabsorption of glucose back into the bloodstream. When glucose is not reabsorbed, it is excreted in the urine, which results in lower glucose levels in the blood. By reducing the reabsorption of glucose, Ertu Tablet 15 mg also reduces the amount of glucose that can be converted to fat, resulting in weight loss.
Ertu Tablet 15 mg can take 1-2 weeks to start working, depending on how quickly the body adjusts to the medication. It may take up to 3 months to achieve the full effect of the medication, as it needs time to adjust to the changes in glucose levels.
Ertu Tablet 15 mg is absorbed rapidly and extensively after oral administration. Peak concentrations of the drug in the plasma are reached 1 hour after administration.
Ertu Tablet 15 mg is primarily eliminated by the kidneys, with only a small amount excreted in the feces. The elimination half-life is approximately 7.5 to 12 hours.
The recommended starting dose of Ertu Tablet 15 mg is 5 mg once daily, with or without food. Dosage may be increased in increments of 5 mg up to a maximum of 15 mg once daily, as tolerated.
Ertu Tablet 15 mg should be taken orally with or without food once daily. It should not be crushed, chewed, or divided. patients who take the drug must also be aware of their fluid intake to prevent dehydration.
Common side effects of Ertu Tablet 15 mg include headache, urinary tract infection, stomach pain, diarrhea, dizziness, fatigue, and increased urination. Less common side effects include hypoglycemia, elevation of liver enzymes, and skin rash.
No specific antidote exists for Ertu Tablet 15 mg overdosage. Symptoms of an overdose may include hypoglycemic episodes, severe gastrointestinal symptoms, polyuria, and dehydration.
Patients should not take Ertu Tablet 15 mg if they have ever had an allergic reaction or if they have any history of kidney problems, bladder cancer, diabetic ketoacidosis, or severe urinary tract infections. Patients should also talk to their doctor if they have had a previous heart attack or stroke. Women who are pregnant or breastfeeding should talk to their doctor before taking Ertu Tablet 15 mg.
Ertu Tablet 15 mg may interact with other medications, including insulin, metformin, glipizide, pioglitazone, and glyburide. Patients should tell their doctor about all medications they are taking, including prescription and over-the-counter medications, vitamins, and herbal supplements.
Patients with impaired kidney function and those with conditions such as congestive heart failure, severe hypo- or hyperglycemia, or diabetic ketoacidosis should talk to their doctor before taking Ertu Tablet 15 mg. Patients with a history of diabetic macular edema should also talk to their doctor.
Ertu Tablet 15 mg may interact with insulin, metformin, glipizide, pioglitazone, glyburide, sulfonylureas, thiazolidinediones, nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and diuretic medications. Patients should tell their doctor about all medications they are taking before starting on Ertu Tablet 15 mg.
Ertu Tablet 15 mg should be taken with food for better absorption. Avoid ingesting grapefruit or grapefruit juice while taking Ertu Tablet 15 mg as it may increase side effects.
Ertu Tablet 15 mg should not be used by pregnant women unless it is absolutely necessary. If a woman becomes pregnant while taking this medication, she should inform her doctor immediately.
Ertu Tablet 15 mg is not recommended for nursing mothers. Women who are breastfeeding should talk to their doctor before starting on Ertu Tablet 15 mg.
In case of an acute overdose, the patient should contact a healthcare professional or poison control center right away for advice. Symptoms of an overdose may include hypoglycemic episodes, gastrointestinal symptoms, polyuria, and dehydration.
Ertu Tablet 15 mg is contraindicated in patients with a history of anaphylaxis or angioedema with SGLT2 inhibitors, patients with known hypersensitivity to Ertu Tablet 15 mg or any of its ingredients, and patients with type 1 diabetes.
Ertu Tablet 15 mg should be taken with food as advised by the doctor. Patients should avoid taking extra doses of the medication or taking it more frequently than what is prescribed.
Ertu Tablet 15 mg should be stored at room temperature in a dry place and away from children and pets. It should be kept away from light and moisture.
The volume of distribution of Ertu Tablet 15 mg is approximately 1,260 L.
The elimination half-life of Ertu Tablet 15 mg is estimated to be 7.5 to 12 hours.
The clearance of Ertu Tablet 15 mg is estimated to be 210 L/hr.
See in details version Ertu Tablet 15 mg also Ertu Tablet 15 mg in bangla